Trial Profile
A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Adverse reactions
- Sponsors Alexion Pharmaceuticals
- 13 Apr 2015 Results published in American Transplant Congress, as per Alexion Pharmaceuticals media release.
- 14 May 2014 New trial record